Kalaris Therapeutics (KLRS) Return on Equity [ROE] (2020 - 2026)
Kalaris Therapeutics' Return on Equity [ROE] was -75.67% in Q2 2026, up 41.05 percentage points from -116.73% a year earlier but down 11.03 percentage points from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Return on Equity [ROE] (2020 - 2026) Analysis & Trends
For FY2023, Return on Equity [ROE] at Kalaris Therapeutics came in at -212.16%, down 137.14 percentage points from FY2022.
- Return on Equity [ROE] has now declined for three consecutive years, with a three-year change of -165.88 percentage points (FY2020 to FY2023).
- In earlier years, Return on Equity [ROE] was -75.02% in FY2022 (-15.55 pp), -59.47% in FY2021 (-13.19 pp) and -46.28% in FY2020.
- Quarterly Return on Equity [ROE] has moved between -254.32% (Q4 2023) and -48.54% (Q3 2021) over five years.
- The best year-over-year quarter for Return on Equity [ROE] over five years was Q2 2026 (a gain of 41.05 percentage points); the worst was Q4 2023 (a drop of 183.69 percentage points).
- Per Business Quant data, KLRS's Return on Equity [ROE] in the three quarters before Q2 2026 was -64.64% (Q1 2026), -78.88% (Q4 2025) and -92.34% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 4.66% |
| 10 | Kalaris Therapeutics | 44.52 Mn | -38.38 Mn | - | -82.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -82.74% |
| Jun 30, 2026 | -70.25% |
| Mar 31, 2026 | -59.91% |
| Dec 31, 2025 | -71.98% |
| Sep 30, 2025 | -116.78% |
| Jun 30, 2025 | -139.60% |
| Dec 31, 2023 | -252.82% |
| Sep 30, 2023 | -79.40% |
| Jun 30, 2023 | -78.76% |
| Mar 31, 2023 | -79.41% |
| Dec 31, 2022 | -70.76% |
| Sep 30, 2022 | -91.86% |
| Jun 30, 2022 | -109.99% |
| Mar 31, 2022 | -88.87% |
| Dec 31, 2021 | -69.84% |
| Sep 30, 2021 | -48.90% |
| Jun 30, 2021 | -37.12% |
| Mar 31, 2021 | -26.81% |
| Dec 31, 2020 | -19.25% |
| Sep 30, 2020 | -35.34% |
API Access
Kalaris Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();